Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
91.68
+0.42 (0.46%)
At close: Apr 24, 2026, 4:00 PM EDT
91.27
-0.41 (-0.45%)
After-hours: Apr 24, 2026, 7:25 PM EDT
Nektar Therapeutics Employees
Nektar Therapeutics had 63 employees as of December 31, 2025. The number of employees increased by 2 or 3.28% compared to the previous year.
Employees
63
Change (1Y)
2
Growth (1Y)
3.28%
Revenue / Employee
$876,698
Profits / Employee
-$2,604,381
Market Cap
3.09B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 63 | 2 | 3.28% |
| Dec 31, 2024 | 61 | -76 | -55.47% |
| Dec 31, 2023 | 137 | -79 | -36.57% |
| Dec 31, 2022 | 216 | -524 | -70.81% |
| Dec 31, 2021 | 740 | 22 | 3.06% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Arcus Biosciences | 601 |
| Beam Therapeutics | 511 |
| Denali Therapeutics | 503 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 258 |
| Vera Therapeutics | 249 |
| Alumis | 224 |
| Structure Therapeutics | 220 |
NKTR News
- 2 days ago - Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 4 days ago - Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering - PRNewsWire
- 5 days ago - Nektar Therapeutics Announces Proposed Public Offering - PRNewsWire
- 5 days ago - This Biotech Stock Soars on Hair Loss Trial Results. It's Not a Cure for Baldness. - Barrons
- 5 days ago - Why Are Nektar Shares Up Monday? - Benzinga
- 5 days ago - Nektar Therapeutics Transcript: Study update - Transcripts
- 5 days ago - 52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin - PRNewsWire
- 6 days ago - Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026 - PRNewsWire